Biocon arm, CHAI in pact on affordable cancer therapies


Biocon Biologics, a pure-play biosimilars firm and subsidiary of Biocon Ltd., has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to life-saving cancer biosimilars in more than 30 countries in Africa and Asia, as part of the Cancer Access Partnership (CAP).

As per the agreement, Biocon Biologics would aim to deliver affordable biosimilar cancer therapies in 25 countries in Africa and five countries in Asia, currently covered under CAP, led by the CHAI.

The company would initially supply bTrastuzumab and bPegfilgrastim and expand the arrangement to include other biosimilars.

The partnership was a significant step in delivering advanced cancer therapies to patients who needed them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries, said the company.

You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Briefing

We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.

.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.